Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

por Wolf, E, Blankenburg, M, Bogner, JR, Becker, W, Gorriahn, D, Mueller, MC, Jaeger, H, Welte, R, Baudewig, M, Walli, R, Stoll, M
Publicado 2010